Author

S. Kaila

Observed institutions: Boehringer Ingelheim (United States), Janssen Scientific Affairs (United States)

OpenAlex ID: A5111020730

P16 Health-related Quality of Life for Frail Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab, Lenalidomide and Dexamethasone: Subgroup Analysis of Maia Trial

2023 · T. Facon, T. Plesner, et al. · HemaSphere · 2

Assessment Of Spirometry Testing And Inpatient Readmission In Patients With Chronic Obstructive Pulmonary Disease

2014 · Y. Yu, J. Meyers, et al. · Value in Health · 1

Pb2003: Real-world Duration of Use and Dosing Frequency of Daratumumab in Patients With Multiple Myeloma in the U.s.

2022 · R. Fonseca, E. Chinaeke, et al. · HemaSphere

Factors Associated With Chronic Obstructive Pulmonary Disease-Related Inpatient Readmissions

2014 · J. Meyers, Y. Yu, et al. · Value in Health

Works count: 4

Citation count: 3

H-index: 1

I10-index: